Adverum Biotechnologies, Inc. (ADVM)
Stock Price:
$14.90 USD
-0.69 (-4.43%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $15.53 +0.63 (4.23%) Aug 12, 6:02 PM
Key Info
| Market Cap |
1.20B |
| Revenue (ttm) |
250,000 |
| Net Income (ttm) |
-87.15M |
| Shares Out |
80.30M |
| EPS (ttm) |
-1.24 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$14.90 |
| Previous Close |
$15.59 |
| Change ($) |
-0.69 |
| Change (%) |
-4.43% |
| Day's Open |
14.93 |
| Day's Range |
13.36 - 15.97 |
| Day's Volume |
2,173,440 |
| 52-Week Range |
4.96 - 26.98 |
More Stats
| Market Cap |
1.20B |
| Enterprise Value |
942.52M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
80.30M |
| Float |
51.65M |
| EPS (basic) |
-1.22 |
| EPS (diluted) |
-1.24 |
| FCF / Share |
-0.96 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.93M |
| Short Ratio |
12.28 |
| Short % of Float |
16.24% |
| Beta |
2.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4,785.62 |
| PB Ratio |
4.45 |
| Revenue |
250,000 |
| Operating Income |
-90.30M |
| Net Income |
-87.15M |
| Free Cash Flow |
-76.78M |
| Net Cash |
253.88M |
| Net Cash / Share |
3.16 |
| Gross Margin |
-16,067.60% |
| Operating Margin |
-36,120.80% |
| Profit Margin |
-34,859.60% |
| FCF Margin |
-30,712.00% |
| ROA |
-20.86% |
| ROE |
-37.87% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$26.50*
(77.85% upside)
Low
20.0
Current: $14.90
High
36.0
Target: 26.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.25 | 1.61 | 1.85 | 1.46 | 2.32 | 0.57 | 0.48 | 0.03 |
| Revenue Growth | -84.49% | -12.82% | 27.08% | -37.26% | 305.42% | 19.17% | 1500% | - |
| Gross Profit | 0.25 | 1.61 | 1.85 | 1.46 | 2.32 | 0.57 | 0.48 | 0.03 |
| Operating Income | -68.55 | -78.08 | -58.85 | -115 | -47.82 | -24.40 | -3.45 | -1.82 |
| Net Income | -64.49 | -72.63 | -56.15 | -114 | -47.45 | -25.40 | -5.28 | -1.81 |
| Shares Outstanding | 64.10 | 61.38 | 43.66 | 36.25 | 25.48 | 11.65 | 3.67 | 3.64 |
| Earnings Per Share | -1.01 | -1.18 | -1.29 | -3.14 | -1.86 | -2.46 | -1.44 | -0.50 |
| Operating Cash Flow | -49.17 | -53.96 | -45.42 | -38.37 | -35.34 | -5.65 | -2.18 | -1.27 |
| Capital Expenditures | -19.25 | -0.81 | -1.02 | -2.41 | -2.99 | -0.94 | -0.09 | - |
| Free Cash Flow | -68.42 | -54.77 | -46.44 | -40.78 | -38.33 | -6.59 | -2.27 | -1.27 |
| Cash & Equivalents | 167 | 206 | 190 | 222 | 259 | 159 | 0.56 | 0.36 |
| Total Debt | 28.21 | - | - | - | - | - | - | 0.49 |
| Net Cash / Debt | 139 | 206 | 190 | 222 | 259 | 159 | 0.56 | -0.13 |
| Assets | 223 | 213 | 202 | 235 | 264 | 162 | 1.09 | 0.39 |
| Liabilities | 47.77 | 12.33 | 17.88 | 18.98 | 11.73 | 12.42 | 1.30 | 1.38 |
| Book Value | 175 | 201 | 184 | 216 | 253 | 149 | -8.21 | -3.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adverum Biotechnologies, Inc. |
| Country |
United States |
| Employees |
114 |
| CEO |
Laurent Fischer |
Stock Information
| Ticker Symbol |
ADVM |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: ADVM |
| IPO Date |
July 31, 2014 |
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.